Tobacco smoking is a global health problem with serious and far-reaching consequences 7.
Substances from tobacco smoke may affect brain functions via several neurotransmitter systems 7. Smoking is related to different neuro-psychiatric disorders and altered behaviors, eliciting functional and structural changes in the brain, and might represent a risk factor for suicide 7. Tobacco-related ailments, including heart diseases, pulmonary diseases, lung cancer and other malignancies, kill one in 10 adults 43. According to the report on global smoking statistics issued by WHO in 2002, smoking will kill one in six people by the year 2030. One-third of adults in Croatia smoke, resulting in the smoking prevalence of 36%, which is higher than the respective prevalence of 33% in most European Union countries 22.
The First Croatian Health Project showed that 34% of males and 27% of females smoke regularly 40. In addition, within the population of smokers in Croatia, 74% start smoking before the age of 20 40.
Environmental, biological and genetic factors are involved in smoking behavior, smoking initiation, regular tobacco use, and nicotine dependence 15,19,27,38. Dopamine is a neurotransmitter important in mediating drug reward. Many different drugs have the ability to alter dopamine concentration in reward-relevant regions of the brain 17. Nicotine binds to nicotinic acetylcholine receptors in the brain and stimulates dopamine release and reuptake 30. This leads to the increase in dopamine concentration 19. Dopaminergic system, as well as allelic variations in genes involved in the dopamine pathways, is considered the major risk factor for tobacco use and development of nicotine dependence 17. Candidate genes involved in nicotine dependence include genes for tyrosine hydroxylase (involved in dopamine synthesis), dopamine DRD1-DRD5 receptors; dopamine transporter (involved in dopamine reuptake), catechol-O-methyltransferase (COMT) and monoamine oxidase, and dopamine-beta-hydroxylase (enzymes for dopamine metabolism) 29,33.
COMT is an Mg

2+
-dependent enzyme responsible for degrading catecholamine neurotransmitters (dopamine, epinephrine, norepinephrine) 41. COMT converts dopamine into 3-methoxytyramine and norepinephrine into normetanephrine, by introducing a methyl group derived from S-adenosyl methionine to a hydroxyl group located on a catechol nucleus 1. It has been associated with broad range of psychiatric disorders. COMT gene lies within the q11 band of human chromosome 22 12, and has two promoters, namely P1 and P2 36. The Val variant of COMT is a high (H) activity allele, and has a higher stability and activity, catabolizing dopamine up to four times the rate of its Met alternative (or the low activity (L) allele) 4,34,41.
Several studies investigated the association between COMT Val158Met polymorphism and nicotine dependence with divergent findings. On one hand, no association between COMT polymorphism and smoking initiation, smoking persistence, or smoking cessation has been confirmed 6,11,25, while on the other hand, some studies show significant association between COMT Val158Met polymorphism and nicotine dependence 2,13,32, or smoking cessation 5,28,29. Sex differences can be observed in the genetic origins of smoking 2,10,20, and in the association between COMT Val158Met genotype and smoking behavior 2,5. We tested the hypothesis that COMT Val158Met is associated with smoking in ethnically homogenous sample of healthy male and a smaller group of female Caucasian subjects of European ancestry, pertaining to Croatian origin.
The study included 578 male and 79 female unrelated, medication-free Caucasian healthy subjects of Croatian origin, who were recruited in the period between 2006 and 2009 at the University Hospital Centre Zagreb, Zagreb, Croatia, and who filled in the questionnaire answering the questions about their medical history, smoking and drinking habits. All subjects were categorized into smokers and nonsmokers, with smokers classified as subjects smoking  10 cigarettes per day, and nonsmokers classified as subjects who never smoked in their life.
The average age of male and female subjects was 39.43511.771 and 43.03813.307 years, respectively. All individuals gave their detailed medical history. Inclusion criteria were no current medication therapy; no previous or current psychiatric disorders; no drug or alcohol abuse, nor suicidal attempts; no family history of psychiatric disorders (determined according to the answers of participants about the mental health status of their parents, grandparents, siblings and children); not being related; and belonging to the native ethnic group with at least three generations living in the region. Written informed consent was obtained from all participants, after explaining the aims and procedures of the study, under guidelines approved by the Ethics committee of the University Hospital Centre Zagreb, Zagreb, Croatia. All human studies have been executed with the full cooperation of participants, adequate understanding, and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.
Blood samples (8 ml) were drawn using plastic syringes with 2 ml of acid citrate dextrose anticoagulant at 08.00 h. Genomic DNA was extracted from peripheral blood using the salting out method 26. The COMT val158met polymorphisms was genotyped with the ABI Prism 7000 Sequencing Detection System apparatus (ABI) using the Taqman-based allele-specific polymerase chain reaction assay, according to manufacturers instructions (Applied Biosystems, Foster City, CA, USA). The primers and probes were purchased from Applied Biosystems. The results were expressed as means ± standard deviations (S.D.) and evaluated with Sigma Stat 3.5 (Jandell Scientific Corp. San Raphael, California, USA) and Microsoft Excel. Differences in age were assessed using one-way analysis of variance (ANOVA). The Hardy-Weinberg analysis was used to test the equilibrium of the population. The differences in genotype and allele frequencies were evaluated using the  Due to the fact that gender-gene interaction significantly affects smoking behavior, and smoking was reported to be differently related with COMT val158met polymorphism in female and male subjects 2,5, the effect of smoking was evaluated separately in male and female subjects (Table 1) .
Within larger group of male smokers and nonsmokers ( showing no association between COMT polymorphism and smoking initiation, smoking persistence, smoking cessation or smoking intensity 6,11,13,25,35.
The positive association between Val/Val genotype and smoking, found in the present study, was not confirmed in female subjects due to the substantially smaller female sample size, presumably due to the type I error, which represents a limitation of the study. In contrast to our results, previous studies reported association of Met/Met genotype and higher probability of smoking cessation in women 5. The genetic origin of smoking, smoking initiation and smoking persistence is gender dependent 2,10,20, indicating that the COMT val158met polymorphism affects catecholaminergic systems differently in male and female patients. A possible explanation for this gender-specific association might be due to the effect of estrogen in females, which modulates neurotransmission and neuronal excitability of catecholaminergic systems 14, resulting in different levels of dopamine in the synapse and different influence of dopamine on emotion and motivation among men and women 7. In addition, it has been suggested that gender related differences in smoking behavior might be due to the fact that COMT val158met polymorphism may differently influence personality traits that presumably affect smoking behavior, and that Val/Val genotype may be related to higher novelty or risk seeking traits than carriers of other genotypes 7,10,39. Since no evaluation of personality traits in male subjects was performed in the present study, we can neither confirm nor exclude these presumptions. The data, showing increased tendency towards smoking in Val/Val male homozygotes, might be explained by the fact that these subjects, who have high activity COMT variant, are more prone to develop a higher level of dependence and are more predisposed to smoking relapse 5,31. This effect might be mediated by the lower concentration of frontocortical dopamine in carriers of the high activity COMT variant 9. Significant association between Val/Val genotype and smoking might also be due to the fact that the Val/Val genotype may represent a risk factor for altered brain function and cognition during nicotine abstinence, i.e. a risk factor for increased susceptibility to nicotine dependence and smoking relapse 23. In addition, carriers of Val/Val genotype were shown to have greater release of dopamine induced by smoking than carriers of Met/Met or Met/Val genotypes 3.
In conclusion, the results of the study confirmed a significant association between COMT variants and smoking more than 10 cigarettes per day, compared to complete, lifelong abstinence from smoking in healthy male medication-free Caucasian healthy subjects.
The observed association was due to the higher percent of Val/Val homozygotes in male smokers compared to male nonsmokers. 
